

Resource Summary Report

Generated by [RRID](#) on Aug 5, 2026

[alpha-Tubulin Antibody](#)

RRID:AB_2210548

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 2144, RRID:AB_2210548

Antibody Information

URL: http://antibodyregistry.org/AB_2210548

Proper Citation: Cell Signaling Technology Cat# 2144, RRID:AB_2210548

Target Antigen: alpha-Tubulin

Host Organism: rabbit

Clonality: polyclonal

Comments: Applications: W, IHC-P, IF-IC, F. Consolidation on 9/2016: AB_10699022.

Antibody Name: alpha-Tubulin Antibody

Description: This polyclonal targets alpha-Tubulin

Target Organism: Human, Rat, Bovine, Monkey, Mouse, D. melanogaster

Antibody ID: AB_2210548

Vendor: Cell Signaling Technology

Catalog Number: 2144

Alternative Catalog Numbers: 2144S

Record Creation Time: 20250820T042850+0000

Record Last Update: 20250820T190507+0000

Ratings and Alerts

No rating or validation information has been found for alpha-Tubulin Antibody.

No alerts have been found for alpha-Tubulin Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 151 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Sherman DJ, et al. (2025) PNPLA3-I148M is a neomorph that interferes with two primary hepatic triglyceride clearance pathways. *Cell reports*, 44(10), 116371.

Park Y, et al. (2025) Polychlorinated Biphenyls Alter Estrogen Receptor α -mediated Epigenetic Regulation, Promoting Endometriosis. *Endocrinology*, 166(11).

Brito S, et al. (2025) Age-associated interplay between zinc deficiency and Golgi stress hinders microtubule-dependent cellular signaling and epigenetic control. *Developmental cell*, 60(9), 1304.

Ozawa H, et al. (2025) Targeting KRAS Inhibitor-Resistant Pancreatic Cancer with an MUC1-C Antibody-Drug Conjugate. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(24), 5246.

Zhu J, et al. (2025) FGD3 mediates lytic cell death, enhancing efficacy and immunogenicity of chemotherapy agents in breast cancer. *Journal of experimental & clinical cancer research : CR*, 44(1), 299.

He W, et al. (2025) IGF1 Signaling Regulates Neuropeptide Expression in Hypothalamic Neurons Under Physiological and Pathological Conditions. *Endocrinology*, 166(5).

Lieu DJ, et al. (2025) A bacterial genotoxin reveals a p53-proteasome-LC3 regulatory axis that drives the suppression of autophagy in cells experiencing sublethal DNA damage. *iScience*, 28(4), 112118.

Wang M, et al. (2025) Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors. *Cancer discovery*, 15(9), 1883.

Wang Q, et al. (2025) Cisplatin-Induced APE2 Overexpression Disrupts MYH9 Function and Causes Hearing Loss. *Cancer research communications*, 5(6), 994.

Clark ML, et al. (2025) Mitochondrial complex IV remodeling in tumor-associated macrophages amplifies interferon signaling and promotes anti-tumor immunity. *Immunity*, 58(7), 1670.

Jung MM, et al. (2025) GATA2 decommissioning of enhancers: A mechanism to constrain inflammatory signaling. *Cell reports*, 44(10), 116344.

Chan FHM, et al. (2025) Plasticity of cell death pathways ensures GSDMD activation during *Yersinia pseudotuberculosis* infection. *Cell reports*, 44(1), 115216.

Zhao Z, et al. (2025) Sickle cell disease induces chromatin introversion and ferroptosis in CD8⁺ T cells to suppress anti-tumor immunity. *Immunity*, 58(6), 1484.

Baldacci S, et al. (2025) Eradicating Drug Tolerant Persister Cells in EGFR-Mutated Non-Small Cell Lung Cancer by Targeting TROP2 with CAR-T cellular therapy. *Cancer discovery*.

Xu J, et al. (2025) PARP7 inhibition stabilizes STAT1/STAT2 and relieves experimental autoimmune encephalomyelitis in mice. *Cell reports*, 44(8), 116130.

Sehgal P, et al. (2025) NRCAM variant defined by microexon skipping is a targetable cell surface proteoform in high-grade gliomas. *Cell reports*, 44(8), 116099.

Huang Z, et al. (2025) RIOK3 mediates the degradation of 40S ribosomes. *Molecular cell*, 85(4), 802.

Wu M, et al. (2025) Genomic copy-number variants drive apoptotic evasion underlying acquired resistance to immune checkpoint inhibitors. *Immunity*, 58(11), 2864.

Nógrádi-Halmi D, et al. (2025) Kynurenic Acid Protects Against Myocardial Ischemia/Reperfusion Injury by Activating GPR35 Receptors and Preserving Mitochondrial Structure and Function. *Biomolecules*, 15(10).

Hirano S, et al. (2025) Dual molecular therapy targeting tumor cell heterogeneity improves therapeutic efficacy in glioblastoma. *iScience*, 28(9), 113456.